Juvenile Dermatomyositis
Conditions
Keywords
intravenous methylprednisolone repeated intermittent pulse, mycophenolate mofetil
Brief summary
This study aimed to investigate the clinical effectivity of intravenous methylprednisolone repeated intermittent pulse combined with mycophenolate mofetil in the treatment of newly diagnosed juvenile dermatomyositis.
Detailed description
Reviewed the clinical data of 12 juvenile dermatomyositis patients, from January 2014 to January 2017, hospitalized and treated with intravenous methylprednisolone repeated intermittent pulse combined with mycophenolate mofetil
Interventions
OTHERobservation
investigate the clinical effectivity of intravenous methylprednisolone repeated intermittent pulse combined with mycophenolate mofetil in the treatment of newly diagnosed juvenile dermatomyositis
Sponsors
The First Hospital of Jilin University
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 16 Years
Healthy volunteers
No
Inclusion criteria
1. patients with age of JDM onset \<16 years 2. newly treated cases 3. no contraindications to corticosteroids 4. provide signed informed consent form 5. regular follow-up for more than 30 months.
Exclusion criteria
1. patients with serious complications of heart, liver and kidney 2. patients with a history of contraindications and/or allergies to GC 3. patients who underwent treatment before admission 4. patients who failed to regularly follow-up 5. patients with positive anti-melanoma differentiation-associated gene 5 (MDA5) antibodies
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in CMAS score | 1, 3, 6, 12, 18, 24 and 36 months | CMAS score is an index to assess the disease activity of JDM |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes from baseline of the patient's height percentile in the same age and sex crowd. | 1, 3, 6, 12, 18, 24 and 36months | the patient's height percentile in the same age and sex crowd is one of safety evaluation indicators. |
| Changes from baseline of the patient's weight percentile in the same age and sex crowd. | 1, 3, 6, 12, 18, 24 and 36months | the patient's weight percentile in the same age and sex crowd is one of safety evaluation indicators. |
| intraocular pressure | 1, 3, 6, 12, 18, 24 and 36months | the patient's intraocular pressure is one of safety evaluation indicators. |
| triglycerides | 1, 3, 6, 12, 18, 24 and 36months | the patient's triglycerides is one of safety evaluation indicators. |
Outcome results
None listed